Research programme: cannabinoid prodrugs - Vitality Biopharma

Drug Profile

Research programme: cannabinoid prodrugs - Vitality Biopharma

Alternative Names: Cannabinoid glycosides - Vitality Biopharma; Cannabinosides - Vitality Biopharma

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Vitality Biopharma
  • Class Antiepileptic drugs; Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epilepsy; Guillain-Barre syndrome; Huntington's disease; Inflammatory bowel diseases; Pain; Schizophrenia

Most Recent Events

  • 10 May 2017 Vitality Biopharma has patent protection for cannabinoid prodrugs
  • 05 Apr 2017 Vitality Biopharma files for International patent protection for cannabinoid prodrugs
  • 16 Nov 2016 Early research in Pain (narcotic bowel syndrome) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top